Multiplex detection of multiple genetic markers
Multiplexing in oncology assays enables the simultaneous detection and analysis of multiple genetic markers, allowing pathologists to gain a comprehensive profile of the tumor, leading to more accurate diagnostics, targeted therapies, and personalized treatment strategies. However, the challenge with multiplex assays is the inherent variability between the physicochemical characteristics (e.g., length, GC content) of the amplified sequences, flanking regions, and secondary structures which can impact Ct values and create an imbalance in the amplification of certain targets. Meridian’s enzymes and qPCR master mixes are formulated for multiplex amplification under a wide range of temperatures, reaction and cycling conditions, and specimen types (blood, saliva, urine, and stool). They are ideal for multiplex assays, and ensure that amplification is consistent across all the assay targets, allowing for accurate and reliable results for each analyte.
Fast and More Sensitive Detection of Cancer Markers in Urine Samples
CDC2
IGFBP5
MDK
Figure 6. Three tumor-related mRNA markers (CDC2 kinase, IGFBP5 and MDK) were amplified from total RNA (from a bladder cancer patient) in a triplex reaction using lyophilized Lyo-Ready ™ Direct RNA/DNA qPCR Urine (MDX153, red ) or liquid BioRad Reliance One-Step Multiplex Supermix ™ ( purple ) in the presence of 10% Human Urine. The results illustrate that Lyo-Ready ™ Direct RNA/DNA qPCR Urine (MDX153) is able to detect cancer related RNA markers from urine faster and with higher sensitivity compared to the other mix.
MDX153 | BioRad Reliance 1-Step
Powered by FlippingBook